Last reviewed · How we verify
NCT05640115
Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent
EARLY_PHASE1 trial testing Ureteral Stent in Cancer. Withdrawn.
21 August 2024
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Start date | 22 September 2023 |
| Primary completion | 21 August 2024 |
| Estimated completion | 21 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ureteral Stent
- Percutaneous Nephrostomy Tube Placement
Conditions studied
- Cancer — all drugs for Cancer →
- Urinary Obstruction — all drugs for Urinary Obstruction →
- Malignancy — all drugs for Malignancy →
- Urinary Dysfunction — all drugs for Urinary Dysfunction →
Sponsor
University of Chicago
Who can join
18 and older, any sex, with Cancer or Urinary Obstruction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study will compare two procedures commonly used to treat urinary obstruction due to cancer. Sometimes cancer blocks one or both ureters (narrow tubes in the body that carry urine from the kidneys to the bladder). When these ureters become blocked, the body can no longer properly drain urine. This blocking of the ureters is called urinary obstruction, which can lead to kidney problems, infection, and pain. Treatment options for urinary obstruction include ureteral stent placement and percutaneous nephrostomy tube placement. Both treatment options require a doctor to place soft tubes (like a catheter) inside the body to help the ureters properly drain urine. These two treatment options have different success rates, risks, and effects on quality of life. By doing this study, researchers hope to learn which treatment option is best for individuals who develop urinary obstruction because of cancer. Participation in this research will last about 3 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05640115
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05640115 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 19 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05640115.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing